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Biochemical Markers in 

Cancer of the Ovary: A Review 

The ideal tumour marker would be 
one which is detectable before 
obvious clinical involvement, follows 
the kinetics of tumour growth with 
reduction in serum concentration 
as the tumour mass is reduced by 
surgery or chemotherapy, and which 
reappears several months before 
clinical reappearance of the tumour. 
With the possible exception of beta 
HCG in trophoblastic tumours, there 
is no such biochemical marker, and 
one has to rely on a number of 
different parameters for the 
assessment of tumour growth. 
A number of biochemical markers 
have been used to diagnose 
carcinoma of the ovary. 
CA125 is an ovary associated 
antigen detectable by monoclonal 
antibodies, and for which sensitive 
immuno-assays have been 
developed.(l) The antigen is found 
in sera from patients with ovarian 
cancer, amniotic fluid, human milk, 
as well as supernatants from cancer 
clones in vitro. By specific immuno­
histochemical labelling, it has been 
found in a number of tissues 
including benign, borderline and 
most malignant serious tumours of 
the ovary, as well as in some 
Mullerian and some mucinous 
tumours. It is also found in non­
gynaecological tumours such as 
tumours of the lung, liver, stomach, 
gall bladder, pancreas, kidney and 
large bowel. 
Normal serum levels are usually 
taken as below 35 U/mL. In 
carcinoma of the ovary, elevated 
levels (greater than 35 U/mL) are 
found in 80 - 85% of patients overall, 
and in more than 90% of patients 
with stage II to stage IV cancer. 
Estimation of serum CA125 levels 
have been found to be of value. The 
prognosis is significantly better for 
those with pre- operative levels of 
CA125 less th an 65 UhnL. 
Post-operatively, CA125 levels 
usually drop and it has been shown 
that the prognosis is worse in those 
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patients where CA125 levels 
remains greater than 65 UhnL. It 
has been found useful also before 
undertaking a "second look" 
operation, because of the good 
correlation between serum CA125 
levels and visible tumour (positive 
predicative value of 94.5%). (2-5). A 
rising level of CA125 is an ominous 
sign, and therefore our practice is to 
assess CAl25 at regular intervals 
(every 1-3 months). Elevated CA125 
precedes clinical recurrence by up 
to 6 months. 
Some of the problems associated 
with using CA125 levels in diagnosis 
of tumours of the ova:ry include the 
following: 
It is elevated in 2% of normal healthy 
subjects, usually at low levels Oess 
than 100 U/mL). It is elevated 
during menstruation and 
pregnancy, where high levels can be 
seen. It can also be elevated in 
endometriosis and in any conditions 
where there is irritation of the 
peritoneum. Other conditions where 
CA125 has been found elevated 
including endometrial cancer, 
salpingitis, uterine myoma, gastro­
intestinal tract disorders, renal 
disease and renal failure, as well as 
in diabetics. 
In spite of all these provisos, CAl25 
has been found useful and is a 
standard test in the workup and 
follow-up of patients with carcinoma 
of the ovary. 
Figure 1 shows the typical pattern 
of serum levels variations in a 
patient with cancer of the ovary on 
treatment. 
OTHER OVAIUAN TUMOUR 
MARKERS 
TISSUE POLYPEPTIDE 

ANTIGEN (TPA): 

Elevated levels have been found in 
over 70% of patients with advanced 
cancer of the ovary, (the normal 
range being less than 85mU/ml).(4) 
It is positive also in up to 54% of 
non-ovarian tumours. However, the 
specificity and sensitivity are not as 
good as for CA125. In view of the 
tact that it bears no correlation with 
histological type, it could be useful 
in detecting those patients who are 
CA125 negative. 
LIPID - ASSOCIATED SIALIC 

ACID (LASA-P) 

This non-specific sialo glycoprotein 
on the cell surface of cancer cells is 
found elevated in the sera of most 
patients with ovarian cancer and 
normal in the ~ority of patients 
with benign ovarian neoplasms. It 
correlates fairly well with CA125 
levels. It does not require 
immunoassay, and this could be 
advantageous in some laboratories 
(6). 
CA 19-9 
This antigen, a carbohydrate 
determinant related to the Lewis 
blood type (more specifically a 
ganglioside containing sialylated 
lacto - N Fucopentose), was first 
extracted from gastro- intestinal 
tumours. Immunoradio-metric 
assays are available, and serum 
levels less than 40 U/mL are 
considered abnormal. Elevated 
levels have been found in up to 93% 
of ovarian cancer and not in benign 
tumours of the ovary or healthy 
subjects (7,8). Mucinous (as well as 
serious) epithelial tumours of the 
ovary have 
a tendency to have high levels and 
therefore this test coUld 
prove useful for detection and follow­
up of those ovarian 
cancers which are negative for 
CA125. 
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CARCINOEMBRYONIC 

ANTIGEN (CEA) 

Carcinoembrionic antigen was 
originally extracted from tumours 
of the colon (9) and 
immunofluorescent studies 
confirmed that it is present in 
abundant quantities in mucinous 
carcinomas of the colon. It is also 
present in mucinous 
adenocarcinoma of the ovary, endo­
cervix, and to a lesser extent 
endometrium. 
Sensitive immuno-assays have been 
developed to detect levels of CEA in 
the serum. CEA is elevated in only 
a small proportion of cancer patients 
and then only in advanced stages ill 
and IV. Only 50% of ovarian cancer 
patients have elevated CEA at any 
time during serum measurements. 
A number of studies (10,11) have 
shown that CEA estimation is 
of limited value. We found the 
sensitivity to be only 70%, and 
a positive predicative value of 46% 
at a cut-off level of 5nWml. 
A high level of CEA is likely to be 
present when there is a large 
tumour mass. Prognosis is likely to 
be worse when levels of these 
markers are high (12), presumably 
because this implies a more wide 
spread or more bulky tumour. 
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However, as it is a mucus-related 
antigen, it may detect those 
mucinous tumours not detectable 
by other markers. 
ALPHA FETO PRO'lEIN AND 
·BETA BCG 
These markers are present only in a 
very small proportion of patients 
with ovarian tumours, and only in 
those with germ cell components. 
While extremelY useful for the latter 
group, it is unlikely that they will be 
of any great relevance for the vast 
majority of ovarian cancer detection. 
Other markers being investigated 
include NBI70k; HMFG2, DCA, 
MSA, B2 microglobulin, placental 
alkaline phosphatase etc. (13,14). 
SCREENING FOR OVARIAN 

CARCINOMA IN A NORMAL 

POPULATION 

Attempts have been made recently 
to assess the value of CA125 for 
screening normal (post menopausal) 
populations to determine the 
possible value of screening tests in 
the detection of cancer. Surveys are 
being carried out in our hospital 
and elsewhere (15,16) to evaluate 
use of CA125 with or without other 
modalities in the detection of 
carcinoma of the ovary. 
chemotherapy 
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